ACM
SGMT icon

Altium Capital Management’s Sagimet Biosciences SGMT Stock Holding History

Altium Capital Management’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-483,181
Closed -$2.53M – 90
2023
Q4 		$2.53M Hold
483,181
– – 1.72% 19
2023
Q3 		$4.25M Buy
+483,181
New +$6.43M 2.22% 17

Other funds holding SGMT

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Altium Capital Management's SGMT Position: Q1 2024 in Review

Altium Capital Management sold out of Sagimet Biosciences (SGMT) in Q1 2024, closing a stake of 483,181 shares — an estimated $2.53M sold.

Altium Capital Management first reported a position in SGMT in Q3 2023 and held it in 2 quarters. The position peaked at $4.25M in Q3 2023. 81 funds tracked by Wall St. Rank hold SGMT as of Q1 2024.

  • Altium Capital Management reported no remaining Sagimet Biosciences position as of Q1 2024 after selling out during the quarter.
  • Altium Capital Management sold 483,181 Sagimet Biosciences shares in Q1 2024, an estimated $2.53M.
  • Altium Capital Management first reported a position in Sagimet Biosciences in Q3 2023 and held it in 2 quarters.
  • Altium Capital Management's Sagimet Biosciences position peaked at $4.25M in Q3 2023.
  • 81 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q1 2024.

Based on Altium Capital Management's 13F filing for Q1 2024, filed 15 May 2024.